On March 20, 2026, Plus Therapeutics, Inc. announced the appointment of Ronald A. Andrews to its Board of Directors, effective immediately. This decision comes in the wake of Dr. Robert Lenk's resignation from the Board and the Nominating and Corporate Governance Committee. The company confirmed that Dr. Lenk's departure was not due to any disagreements regarding the company's operations or policies. Mr. Andrews, who is recognized as an independent director under Nasdaq listing standards, brings over 35 years of experience in the diagnostics and molecular diagnostics industry. He has held various leadership roles, including President and CEO positions at Twin Strand Biosciences and Oncocyte Inc. His extensive background in strategic consulting and corporate governance is expected to enhance the Board's effectiveness. Mr. Andrews will also serve on the Nominating and Corporate Governance Committee. The Board believes that his qualifications and experience will significantly contribute to the company's strategic direction and operational execution. The appointment is seen as a positive step for Plus Therapeutics, potentially leading to improved governance and strategic oversight as the company continues to navigate the complexities of the biotechnology sector.

Press Release distribution

National Press Distribution across U.S. Media. Direct Access to Key Decision Making Editors.